Immune Checkpoint Inhibitors Future Market Positioning

Immune Checkpoint Inhibitors Market Top Companies and Their Offerings

What are the Recent Developments in the Immune Checkpoint Inhibitors Market?

• In January 2026, for U.S. adults suffering from mCSCC or laCSCC and unable to receive curative radiation or curative surgery, UNLOXCYT™ (cosibelimab-ipdl) was launched by Sun Pharmaceutical Industries Limited. UNLOXCYT is a novel anti–PD-L1 antibody promoting an evolution in checkpoint inhibition, which offers a combination of proven tolerability and durable efficacy for patients with metastatic or unresectable CSCC.
• In August 2025, the launch of HETRONIFLY™ (Serplulimab), the first PD-1 inhibitor in the Indian market, which is a globally approved treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC), was announced by Intas Pharmaceuticals. To solidify the Intas Oncology portfolio and deliver cutting-edge therapies to Indian patients, this product was launched by a strategic licensing agreement between Shanghai Henlius Biotech and Intas Pharmaceuticals.

Immune Checkpoint Inhibitors Market Value Chain Analysis

R&D

• The R&D of the immune checkpoint inhibitors focuses on the development of next-generation combinations, subcutaneous delivery systems, and the discovery of novel targets.
• Key players: Merck & Co., Roche, Bristol Myers Squibb.

Clinical Trials and Regulatory Approvals

• The safety profiles, biomarker expression, progression-free survival, and overall survival are evaluated in the clinical trials and regulatory approvals of the immune checkpoint inhibitors.
• Key players: Merck & Co., Roche, Bristol Myers Squibb.

Packaging and Serialization

• The packaging and serialization of the immune checkpoint inhibitors involves the use of tamper-evident, temperature-controlled packaging and unique 2D DataMatrix barcodes.
• Key players: Merck & Co., Roche, Bristol Myers Squibb.

Distribution to Hospitals, Pharmacies

• Highly specialised cold chain logistics networks and major wholesalers are responsible for the distribution of immune checkpoint inhibitors to the hospitals and pharmacies.
• Key players: McKesson, Cardinal Health, and AmerisourceBergen.

Patient Support and Services

• Financial assistance, educational resources, and insurance navigation are provided in the patient support and services of the immune checkpoint inhibitors.
• Key players: Merck & Co., Roche, Bristol Myers Squibb.

Market Growth

The global immune checkpoint inhibitors market size was estimated at USD 58.72 billion in 2025 and is predicted to increase from USD 65.09 billion in 2026 to approximately USD 164.34 billion by 2035, expanding at a CAGR of 10.84% from 2026 to 2035.